139 related articles for article (PubMed ID: 36915818)
1. Development and validation of a prognostic model for HER2-low breast cancer to evaluate neoadjuvant therapy.
Li X; Lin Z; Yu Q; Qiu C; Lai C; Huang H; Zhang Y; Zhang W; Zhu J; Huang X; Li W
Gland Surg; 2023 Feb; 12(2):183-196. PubMed ID: 36915818
[TBL] [Abstract][Full Text] [Related]
2. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
3. Machine Learning Frameworks to Predict Neoadjuvant Chemotherapy Response in Breast Cancer Using Clinical and Pathological Features.
Meti N; Saednia K; Lagree A; Tabbarah S; Mohebpour M; Kiss A; Lu FI; Slodkowska E; Gandhi S; Jerzak KJ; Fleshner L; Law E; Sadeghi-Naini A; Tran WT
JCO Clin Cancer Inform; 2021 Jan; 5():66-80. PubMed ID: 33439725
[TBL] [Abstract][Full Text] [Related]
4. Early prediction of treatment response to neoadjuvant chemotherapy based on longitudinal ultrasound images of HER2-positive breast cancer patients by Siamese multi-task network: A multicentre, retrospective cohort study.
Liu Y; Wang Y; Wang Y; Xie Y; Cui Y; Feng S; Yao M; Qiu B; Shen W; Chen D; Du G; Chen X; Liu Z; Li Z; Yang X; Liang C; Wu L
EClinicalMedicine; 2022 Oct; 52():101562. PubMed ID: 35928032
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive imaging signatures of HER2 and HR using ADC in invasive breast cancer: repeatability, reproducibility, and association with pathological complete response to neoadjuvant chemotherapy.
Teng X; Zhang J; Zhang X; Fan X; Zhou T; Huang YH; Wang L; Lee EYP; Yang R; Cai J
Breast Cancer Res; 2023 Jun; 25(1):77. PubMed ID: 37381020
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI.
Braman NM; Etesami M; Prasanna P; Dubchuk C; Gilmore H; Tiwari P; Plecha D; Madabhushi A
Breast Cancer Res; 2017 May; 19(1):57. PubMed ID: 28521821
[TBL] [Abstract][Full Text] [Related]
7. Quantitative digital histopathology and machine learning to predict pathological complete response to chemotherapy in breast cancer patients using pre-treatment tumor biopsies.
Saednia K; Lagree A; Alera MA; Fleshner L; Shiner A; Law E; Law B; Dodington DW; Lu FI; Tran WT; Sadeghi-Naini A
Sci Rep; 2022 Jun; 12(1):9690. PubMed ID: 35690630
[TBL] [Abstract][Full Text] [Related]
8. Prediction of pathologic complete response to neoadjuvant chemotherapy using machine learning models in patients with breast cancer.
Kim JY; Jeon E; Kwon S; Jung H; Joo S; Park Y; Lee SK; Lee JE; Nam SJ; Cho EY; Park YH; Ahn JS; Im YH
Breast Cancer Res Treat; 2021 Oct; 189(3):747-757. PubMed ID: 34224056
[TBL] [Abstract][Full Text] [Related]
9. Prediction of clinicopathological features, multi-omics events and prognosis based on digital pathology and deep learning in HR
Hu J; Lv H; Zhao S; Lin CJ; Su GH; Shao ZM
J Thorac Dis; 2023 May; 15(5):2528-2543. PubMed ID: 37324098
[TBL] [Abstract][Full Text] [Related]
10. Prediction of Tumor Shrinkage Pattern to Neoadjuvant Chemotherapy Using a Multiparametric MRI-Based Machine Learning Model in Patients With Breast Cancer.
Huang Y; Chen W; Zhang X; He S; Shao N; Shi H; Lin Z; Wu X; Li T; Lin H; Lin Y
Front Bioeng Biotechnol; 2021; 9():662749. PubMed ID: 34295877
[No Abstract] [Full Text] [Related]
11. Development and validation of a prognostic 15-gene signature for stratifying HER2+/ER+ breast cancer.
Liu Q; Huang S; Desautels D; McManus KJ; Murphy L; Hu P
Comput Struct Biotechnol J; 2023; 21():2940-2949. PubMed ID: 37216014
[TBL] [Abstract][Full Text] [Related]
12. Prognoses of Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy before Surgery: A Retrospective Analysis.
Zhang S; Liu Y; Liu X; Liu Y; Zhang J
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831499
[TBL] [Abstract][Full Text] [Related]
13. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
14. Individualized model for predicting pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: A multicenter study.
Qian B; Yang J; Zhou J; Hu L; Zhang S; Ren M; Qu X
Front Endocrinol (Lausanne); 2022; 13():955250. PubMed ID: 36060977
[TBL] [Abstract][Full Text] [Related]
15. Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer.
Xiao Y; Ding J; Ma D; Chen S; Li X; Yu K
Front Immunol; 2022; 13():877825. PubMed ID: 35663978
[TBL] [Abstract][Full Text] [Related]
16. Impact of Human Epidermal Growth Factor Receptor 2 (HER2) Low Status in Response to Neoadjuvant Chemotherapy in Early Breast Cancer.
Alves FR; Gil L; Vasconcelos de Matos L; Baleiras A; Vasques C; Neves MT; Ferreira A; Fontes-Sousa M; Miranda H; Martins A
Cureus; 2022 Feb; 14(2):e22330. PubMed ID: 35371692
[TBL] [Abstract][Full Text] [Related]
17. [Predictive values of pathologic complete response for patient outcome in different molecular subtypes of breast cancer].
Liu W; Li JB; Wang T; Bian L; Zhang SH; Zhang HQ; Zhou JM; Song ST; Jiang ZF
Zhonghua Yi Xue Za Zhi; 2016 Sep; 96(36):2898-2902. PubMed ID: 27760635
[No Abstract] [Full Text] [Related]
18. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of morphologic change measurements by ultrasound in predicting pathological response to neoadjuvant chemotherapy in triple-negative and HER2-positive breast cancer.
Ochi T; Tsunoda H; Matsuda N; Nozaki F; Suzuki K; Takei H; Yamauchi H
Breast Cancer; 2021 Jul; 28(4):838-847. PubMed ID: 33560514
[TBL] [Abstract][Full Text] [Related]
20. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
